MXPA01013462A - Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence. - Google Patents

Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence.

Info

Publication number
MXPA01013462A
MXPA01013462A MXPA01013462A MXPA01013462A MXPA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A MX PA01013462 A MXPA01013462 A MX PA01013462A
Authority
MX
Mexico
Prior art keywords
methods
molecules
compositions
useful
stranded dna
Prior art date
Application number
MXPA01013462A
Other languages
Spanish (es)
Inventor
C Satishchandran
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14305999P priority Critical
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to PCT/US2000/017670 priority patent/WO2001004313A1/en
Publication of MXPA01013462A publication Critical patent/MXPA01013462A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression

Abstract

Polynucleotide molecules, which include single stranded DNA or RNA, partially double-stranded DNA, and double-stranded DNA molecules, contain terminator sequences and/or other modifications which suppress the production of unwanted polynucleotide species from these molecules when transfected in a host cell. These molecules are useful in methods for enhancing the efficiency of transcription of a selected polynucleotide sequence in a transfected host cell, and reducing the potential for the products of unwanted transcripts. Further, the methods of the invention are useful in avoiding extinguishing or down regulating the expression of certain polynucleotides present in a host cell or host. These compositions and methods are useful in therapeutic, vaccine, diagnostic and research fields.
MXPA01013462A 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence. MXPA01013462A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14305999P true 1999-07-09 1999-07-09
PCT/US2000/017670 WO2001004313A1 (en) 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence

Publications (1)

Publication Number Publication Date
MXPA01013462A true MXPA01013462A (en) 2002-07-02

Family

ID=22502421

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01013462A MXPA01013462A (en) 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence.

Country Status (9)

Country Link
EP (1) EP1194556A1 (en)
JP (1) JP2003504061A (en)
CN (1) CN1360631A (en)
AU (1) AU783681B2 (en)
BR (1) BR0012325A (en)
CA (1) CA2378653A1 (en)
IL (1) IL147026D0 (en)
MX (1) MXPA01013462A (en)
WO (1) WO2001004313A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
BRPI9908967B1 (en) 1998-03-20 2017-05-30 Benitec Australia Ltd Methods for suppressing, delaying or otherwise reducing the expression of a target gene in a plant cell
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
WO2001068835A2 (en) * 2000-03-13 2001-09-20 Aptagen Method for modifying a nucleic acid
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002077609A2 (en) 2001-03-26 2002-10-03 Message Pharmaceuticals, Inc. Identification of compounds for the treatment or prevention of proliferative diseases
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7858769B2 (en) 2004-02-10 2010-12-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1392341B1 (en) * 2001-06-05 2005-03-30 Curevac GmbH Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof
US7897382B2 (en) 2001-10-22 2011-03-01 Alnylam Pharmaceuticals, Inc. Transfection kinetics and structural promoters
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immunostimulation by chemically modified RNA
EP1623009A4 (en) * 2003-04-22 2008-02-13 Nucleonics Inc Transfection kinetics and structural promoters
US20060019914A1 (en) 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
EP1742958B1 (en) 2004-03-15 2017-05-17 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005238034A1 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
EP1782321A4 (en) 2004-07-23 2009-11-04 Univ North Carolina Methods and materials for determining pain sensitivity and predicting and treating related disorders
WO2007011702A2 (en) 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
AU2006298844B2 (en) 2005-09-20 2012-01-12 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRAN
CA2676143A1 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US8796442B2 (en) 2007-03-21 2014-08-05 Brookhaven Science Associates, Llc. Combined hairpin-antisense compositions and methods for modulating expression
CN105125572A (en) 2009-12-18 2015-12-09 箭头研究公司 Organic compositions to treat hsf1-related diseases
MX2012009318A (en) 2010-02-10 2012-09-07 Novartis Ag Methods and compounds for muscle growth.
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (en) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Engineered nucleic acids and methods for their use
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
MX2014007233A (en) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions.
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587300A (en) * 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1999010509A1 (en) * 1997-08-22 1999-03-04 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services, National Institutes Of Health Polynucleotide inhibition of rna destabilization and sequestration
WO1999014346A2 (en) * 1997-09-19 1999-03-25 Sequitur, Inc. SENSE mRNA THERAPY

Also Published As

Publication number Publication date
JP2003504061A (en) 2003-02-04
IL147026D0 (en) 2002-08-14
WO2001004313A1 (en) 2001-01-18
AU5893700A (en) 2001-01-30
AU783681B2 (en) 2005-11-24
EP1194556A1 (en) 2002-04-10
CN1360631A (en) 2002-07-24
CA2378653A1 (en) 2001-01-18
BR0012325A (en) 2002-05-21

Similar Documents

Publication Publication Date Title
Schmitz et al. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes
Franch et al. Antisense RNA regulation in prokaryotes: rapid RNA/RNA interaction facilitated by a general U-turn loop structure
Fletcher et al. The selenocysteine incorporation machinery: interactions between the SECIS RNA and the SECIS-binding protein SBP2
Nielsen Targeting double stranded DNA with peptide nucleic acid (PNA)
EP1798285B1 (en) Methods and medicament for inhibition the expression of a defined gene
Morris siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code
EP0618925B2 (en) Antisense oligonucleotides
Toulme et al. Antimessenger oligodeoxyribonucleotides: an alternative to antisense RNA for artificial regulation of gene expression—a review
Schmeissner et al. Removal of a terminator structure by RNA processing regulates int gene expression
US20020037525A1 (en) Method for generating transcriptionally active DNA fragments
US6380169B1 (en) Metal complex containing oligonucleoside cleavage compounds and therapies
Chan et al. Dissection of the his leader pause site by base substitution reveals a multipartite signal that includes a pause RNA hairpin
US20030049616A1 (en) Enzymatic synthesis of oligonucleotide tags
KR100354610B1 (en) Antisense Inhibition of ras Gene with Chimeric and Alternating Oligonucleotides
Morgan et al. Rho-dependent termination of transcription. II. Kinetics of mRNA elongation during transcription from the bacteriophage lambda PR promoter.
US8658608B2 (en) Modified triple-helix forming oligonucleotides for targeted mutagenesis
Chin et al. Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids
EP0449972A4 (en) Triple stranded nucleic acid and methods of use
NZ508287A (en) Method for generating highly diverse libraries
GB2397062A (en) RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
Wengel et al. LNA (locked nucleic acid)
EP1458741A4 (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
BR9804896A (en) Isolated and purified DNA, host cell, vector, the chimeric polynucleotide, plasmid and method for increasing transcription of a gene of interest in a host cell
WO2003040366A3 (en) Inhibitor oligonucleotides and their use for specific repression of a gene
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene